Piramal Pharma narrows Q1 loss as revenue jumps 17%, EBITDA nearly doubles

The company reported broad-based growth across its CDMO, hospital generics and consumer healthcare businesses in the June quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *